Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Camillo Porta

Showing results (51-60 of 426) with videos related to

Pageof 43
Sort By:
Anti-Cancer Drugs|May 14, 2009
Sorafenib tosylate in advanced kidney cancer: past, present and futureCamillo Porta, Chiara Paglino, Ilaria Imarisio, et al.
Annals of Translational Medicine|April 30, 2019
Single nucleotide polymorphisms in angiogenesis-related genes and outcomes from antiangiogenic therapies in renal cell carcinoma: really a step towards personalized oncology, or not at all?Camillo Porta, Laura Cosmai, Mimma Rizzo, et al.
European Urology Oncology|April 25, 2026
Discovering Predictive Biomarkers in Renal Cell CarcinomaCamillo Porta, Carlo Ganini, Mimma Rizzo, et al.
Thescientificworldjournal|July 11, 2007
Cytokine-based immunotherapy for advanced kidney cancer: past results and future perspectives in the era of molecularly targeted agentsCamillo Porta, Chiara Paglino, Ilaria Imarisio, et al.
Future Oncology (London, England)|January 10, 2015
Dovitinib (CHIR258, TKI258): structure, development and preclinical and clinical activityCamillo Porta, Palma Giglione, Wanda Liguigli, et al.
Clinical Drug Investigation|June 2, 2011
Bevacizumab plus interferon-α versus sunitinib for first-line treatment of renal cell carcinoma in Italy: a cost-minimization analysisRoberto Ravasio, Cinzia Ortega, Roberto Sabbatini, et al.
Nature Reviews. Clinical Oncology|April 5, 2012
Treatment selection in metastatic renal cell carcinoma: expert consensusBernard Escudier, Cezary Szczylik, Camillo Porta, et al.
Journal of Nephrology|May 8, 2016
Renal toxicity of anticancer agents targeting vascular endothelial growth factor (VEGF) and its receptors (VEGFRs)Laura Cosmai, Maurizio Gallieni, Wanda Liguigli, et al.
International Journal of Molecular Sciences|July 2, 2021
Beyond RAS and BRAF: HER2, a New Actionable Oncotarget in Advanced Colorectal CancerChiara Guarini, Teresa Grassi, Gaetano Pezzicoli, et al.
Frontiers in Oncology|November 4, 2022
Cisplatin-based chemotherapy for the treatment of metastatic collecting duct carcinomas: A real-world, retrospective analysisMimma Rizzo, Silvia Chiellino, Angela Gernone, et al.
Pageof 43

Showing results (51-60 of 426) with videos related to

Sort By:
Pageof 43
Anti-Cancer Drugs|May 14, 2009
Sorafenib tosylate in advanced kidney cancer: past, present and futureCamillo Porta, Chiara Paglino, Ilaria Imarisio, et al.
Annals of Translational Medicine|April 30, 2019
Single nucleotide polymorphisms in angiogenesis-related genes and outcomes from antiangiogenic therapies in renal cell carcinoma: really a step towards personalized oncology, or not at all?Camillo Porta, Laura Cosmai, Mimma Rizzo, et al.
European Urology Oncology|April 25, 2026
Discovering Predictive Biomarkers in Renal Cell CarcinomaCamillo Porta, Carlo Ganini, Mimma Rizzo, et al.
Thescientificworldjournal|July 11, 2007
Cytokine-based immunotherapy for advanced kidney cancer: past results and future perspectives in the era of molecularly targeted agentsCamillo Porta, Chiara Paglino, Ilaria Imarisio, et al.
Future Oncology (London, England)|January 10, 2015
Dovitinib (CHIR258, TKI258): structure, development and preclinical and clinical activityCamillo Porta, Palma Giglione, Wanda Liguigli, et al.
Clinical Drug Investigation|June 2, 2011
Bevacizumab plus interferon-α versus sunitinib for first-line treatment of renal cell carcinoma in Italy: a cost-minimization analysisRoberto Ravasio, Cinzia Ortega, Roberto Sabbatini, et al.
Nature Reviews. Clinical Oncology|April 5, 2012
Treatment selection in metastatic renal cell carcinoma: expert consensusBernard Escudier, Cezary Szczylik, Camillo Porta, et al.
Journal of Nephrology|May 8, 2016
Renal toxicity of anticancer agents targeting vascular endothelial growth factor (VEGF) and its receptors (VEGFRs)Laura Cosmai, Maurizio Gallieni, Wanda Liguigli, et al.
International Journal of Molecular Sciences|July 2, 2021
Beyond RAS and BRAF: HER2, a New Actionable Oncotarget in Advanced Colorectal CancerChiara Guarini, Teresa Grassi, Gaetano Pezzicoli, et al.
Frontiers in Oncology|November 4, 2022
Cisplatin-based chemotherapy for the treatment of metastatic collecting duct carcinomas: A real-world, retrospective analysisMimma Rizzo, Silvia Chiellino, Angela Gernone, et al.
Pageof 43